Innovative Technology GigaGen’s cutting-edge single-cell technology platforms enable the rapid development of novel recombinant polyclonal and monoclonal antibody therapies, presenting opportunities for partners and clients seeking advanced biologics for infectious diseases and oncology.

Strategic Collaborations Recent partnerships with the National Cancer Institute and successful government contracts for biothreats like botulinum neurotoxins position GigaGen as a strategic collaborator for organizations focused on infectious disease and biodefense solutions.

Growing Revenue Potential With revenues estimated between $25M and $50M and ongoing clinical advancements, GigaGen demonstrates strong growth prospects that can attract investment opportunities and licensing partnerships in the biotech space.

Pipeline Expansion GigaGen's focus on diverse antibody therapeutics for immunodeficiency, COVID-19, and cancer creates multiple avenues for product licensing, distribution agreements, and joint ventures with entities interested in immunotherapy innovations.

Funding & Support Supported by a recent $35M funding round and NIH grants, GigaGen is well-positioned to scale its research and development efforts, making it a compelling partner for organizations seeking to collaborate on cutting-edge biotech projects.